Company ProfileAt AVI BioPharma we are focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as select other diseases targets. By leveraging our highly differentiated RNA antisense-based technology platform, we have built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses.
By applying pioneering technologies developed and optimized by AVI, we are able to target a broad range of... More >> | | Stock Information |
|
Recent Press Releases| 02/02/12 | AVI BioPharma to Present Company Overview at the 14th Annual BIO CEO & Investor Conference| Webcast Accessible via AVI Website
BOTHELL, WA, Feb 02, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that Chris Garabedian, AVI's president and CEO, will present a company overview at 9:30 a.m. EST on Tuesday, Feb. 14, at the 14th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City.
The presentation will be webcast live under the events section of AVI's website at www.avibio.com and will be ar... |
|  | | 01/04/12 | AVI BioPharma Data Safety Monitoring Board Reports No Safety Concerns Identified in Phase IIb DMD Clinical Trial, Recommends Continuation of Trial| BOTHELL, WA, Jan 04, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the independent Data Safety Monitoring Board (DSMB) providing oversight for AVI's Phase IIb study of eteplirsen in Duchenne Muscular Dystrophy (DMD) patients has reviewed the 12-week biopsy data from the highest dose cohort (50 mg/kg). Following its assessment of this biopsy data, along with other laboratory results and safety outcomes, the DSMB did ... |
| | | 12/14/11 | AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance| BOTHELL, WA, Dec 14, 2011 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, notifying AVI that for the last 30 consecutive business days the bid price of its common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements set forth in Listing Rule 5450(a)(1). The no... |
| | | 12/09/11 | AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations| New Hire Is Part of Organizational Restructuring Focused on Improving Operational Efficiencies
BOTHELL, WA, Dec 09, 2011 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced the appointment of Jayant Aphale, Ph.D., as Senior Vice President of Technical Operations effective December 12, 2011. Dr. Aphale will have responsibility for all of AVI's internal and outsourced manufacturing activities, with an emphasis on technology transf... |
| |
|
More Releases
In the News | | | King5 Healthlink
Chris Garabedian, CEO and Patrick Iversen, PhD,
Senior Vice President of Research and Innovation
September 8, 2011 | Chris Garabedian, CEO AVI BioPharma
June 10, 2011 | | The New Yorker
Jan. 31, 2011 |
Upcoming EventsMore Events |
